Disease Overview
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain. Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.
Market Snapshot
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain. Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.
Market Snapshot
- The opioid class is set to succeed anticonvulsants as market leader, as Lyrica faces generic competition in all markets.
- Treatment of neuropathic pain has remained stagnant over recent years due to lack of innovation within the pain market.
- The burden of neuropathic pain is difficult to estimate, but is likely high across all analyzed countries.
- Lyrica continues to dominate neuropathic pain; however, revenues are set to fall dramatically following patent expiries.
- Donaperminogene seltoplasmid is the only late-stage therapy to target the underlying cause of pain rather than symptoms.
Table of Contents
FORECAST: NEUROPATHIC PAIN (Published on 31 May 2018)
Overview
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Cymbalta
Product Profile: Gralise
Product Profile: Lidoderm
Product Profile: Lyrica
Product Profile: Nucynta Er
Product Profile (Late Stage): Cebranopadol
Product Profile (Late Stage): Donaperminogene Seltoplasmid
Product Profile (Late Stage): Mirogabalin
Product Profile (Late Stage): Raxatrigine
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Cymbalta
Product Profile: Gralise
Product Profile: Lidoderm
Product Profile: Lyrica
Product Profile: Nucynta Er
Product Profile (Late Stage): Cebranopadol
Product Profile (Late Stage): Donaperminogene Seltoplasmid
Product Profile (Late Stage): Mirogabalin
Product Profile (Late Stage): Raxatrigine
TREATMENT: NEUROPATHIC PAIN (Published on 13 March 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Neuropathic Pain
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Neuropathic Pain
EPIDEMIOLOGY: NEUROPATHIC PAIN (Published on 23 October 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Disease Background
Methodology
Forecast
Bibliography
MARKETED DRUGS: NEUROPATHIC PAIN (Published on 31 May 2018)
Overview
Product Overview
Product Profile: Cymbalta
Product Profile: Gralise
Product Profile: Lidoderm
Product Profile: Lyrica
Product Profile: Nucynta Er
Product Overview
Product Profile: Cymbalta
Product Profile: Gralise
Product Profile: Lidoderm
Product Profile: Lyrica
Product Profile: Nucynta Er
PIPELINE: NEUROPATHIC PAIN (Published on 31 May 2018)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Cebranopadol
Product Profile (Late Stage): Donaperminogene Seltoplasmid
Product Profile (Late Stage): Mirogabalin
Product Profile (Late Stage): Raxatrigine
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Cebranopadol
Product Profile (Late Stage): Donaperminogene Seltoplasmid
Product Profile (Late Stage): Mirogabalin
Product Profile (Late Stage): Raxatrigine
LIST OF FIGURES
Figure 1: Neuropathic pain – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for neuropathic pain
Figure 3: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Drug sales across the US, Japan, and five major EU markets, by drug class, 2017–26
Figure 5: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype, 2017–26
Figure 6: Methodology flow for The authors neuropathic pain forecast
Figure 7: Price sources and calculations, by country
Figure 8: Cymbalta for neuropathic pain – SWOT analysis
Figure 9: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 10: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 11: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Gralise for neuropathic pain – SWOT analysis
Figure 13: The authors drug assessment summary of Gralise for neuropathic pain
Figure 14: The authors drug assessment summary of Gralise for neuropathic pain
Figure 15: Gralise sales for neuropathic pain in the US, 2017–26
Figure 16: Lidoderm for neuropathic pain – SWOT analysis
Figure 17: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 18: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 19: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Lyrica for neuropathic pain – SWOT analysis
Figure 21: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 22: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 23: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Nucynta ER for neuropathic pain – SWOT analysis
Figure 25: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 26: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 27: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017–26
Figure 28: Cebranopadol for neuropathic pain – SWOT analysis
Figure 29: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 30: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 31: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
Figure 32: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
Figure 33: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 34: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 35: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
Figure 36: Mirogabalin for neuropathic pain – SWOT analysis
Figure 37: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 38: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 39: Mirogabalin sales for neuropathic pain in Japan, 2017–26
Figure 40: Raxatrigine for neuropathic pain – SWOT analysis
Figure 41: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 42: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 43: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Figure 44: Surveyed respondents’ neuropathic pain patient caseload, by pain subtype
Figure 45: Surveyed respondents’ neuropathic pain patient caseload, by pain severity
Figure 46: 2010 EFNS recommendations for neuropathic pain
Figure 47: Neuropathic pain pharmacological treatment rates, by pain subtype
Figure 48: Top five therapies among first-line painful diabetic peripheral neuropathy patients, by country (%)
Figure 49: Top five therapies among second-line and beyond painful diabetic peripheral neuropathy patients, by country (%)
Figure 50: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 51: Top five therapies among second-line post-herpetic neuralgia patients, by country (%)
Figure 52: Top five therapies among first-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 53: Top five therapies among second-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 54: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 55: Top five therapies among second-line other chronic neuropathic pain patients, by country (%)
Figure 56: Key unmet needs for neuropathic pain
Figure 57: Trends in total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017–37
Figure 58: Cymbalta for neuropathic pain – SWOT analysis
Figure 59: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 60: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 61: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
Figure 62: Gralise for neuropathic pain – SWOT analysis
Figure 63: The authors drug assessment summary of Gralise for neuropathic pain
Figure 64: The authors drug assessment summary of Gralise for neuropathic pain
Figure 65: Gralise sales for neuropathic pain in the US, 2017–26
Figure 66: Lidoderm for neuropathic pain – SWOT analysis
Figure 67: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 68: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 69: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 70: Lyrica for neuropathic pain – SWOT analysis
Figure 71: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 72: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 73: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 74: Nucynta ER for neuropathic pain – SWOT analysis
Figure 75: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 76: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 77: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017–26
Figure 78: Cebranopadol for neuropathic pain – SWOT analysis
Figure 79: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 80: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 81: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
Figure 82: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
Figure 83: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 84: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 85: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
Figure 86: Mirogabalin for neuropathic pain – SWOT analysis
Figure 87: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 88: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 89: Mirogabalin sales for neuropathic pain in Japan, 2017–26
Figure 90: Raxatrigine for neuropathic pain – SWOT analysis
Figure 91: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 92: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 93: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Figure 2: The authors assessment summary of key marketed and pipeline drugs for neuropathic pain
Figure 3: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Drug sales across the US, Japan, and five major EU markets, by drug class, 2017–26
Figure 5: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype, 2017–26
Figure 6: Methodology flow for The authors neuropathic pain forecast
Figure 7: Price sources and calculations, by country
Figure 8: Cymbalta for neuropathic pain – SWOT analysis
Figure 9: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 10: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 11: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Gralise for neuropathic pain – SWOT analysis
Figure 13: The authors drug assessment summary of Gralise for neuropathic pain
Figure 14: The authors drug assessment summary of Gralise for neuropathic pain
Figure 15: Gralise sales for neuropathic pain in the US, 2017–26
Figure 16: Lidoderm for neuropathic pain – SWOT analysis
Figure 17: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 18: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 19: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Lyrica for neuropathic pain – SWOT analysis
Figure 21: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 22: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 23: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Nucynta ER for neuropathic pain – SWOT analysis
Figure 25: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 26: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 27: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017–26
Figure 28: Cebranopadol for neuropathic pain – SWOT analysis
Figure 29: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 30: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 31: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
Figure 32: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
Figure 33: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 34: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 35: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
Figure 36: Mirogabalin for neuropathic pain – SWOT analysis
Figure 37: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 38: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 39: Mirogabalin sales for neuropathic pain in Japan, 2017–26
Figure 40: Raxatrigine for neuropathic pain – SWOT analysis
Figure 41: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 42: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 43: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Figure 44: Surveyed respondents’ neuropathic pain patient caseload, by pain subtype
Figure 45: Surveyed respondents’ neuropathic pain patient caseload, by pain severity
Figure 46: 2010 EFNS recommendations for neuropathic pain
Figure 47: Neuropathic pain pharmacological treatment rates, by pain subtype
Figure 48: Top five therapies among first-line painful diabetic peripheral neuropathy patients, by country (%)
Figure 49: Top five therapies among second-line and beyond painful diabetic peripheral neuropathy patients, by country (%)
Figure 50: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 51: Top five therapies among second-line post-herpetic neuralgia patients, by country (%)
Figure 52: Top five therapies among first-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 53: Top five therapies among second-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 54: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 55: Top five therapies among second-line other chronic neuropathic pain patients, by country (%)
Figure 56: Key unmet needs for neuropathic pain
Figure 57: Trends in total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017–37
Figure 58: Cymbalta for neuropathic pain – SWOT analysis
Figure 59: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 60: The authors drug assessment summary of Cymbalta for neuropathic pain
Figure 61: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
Figure 62: Gralise for neuropathic pain – SWOT analysis
Figure 63: The authors drug assessment summary of Gralise for neuropathic pain
Figure 64: The authors drug assessment summary of Gralise for neuropathic pain
Figure 65: Gralise sales for neuropathic pain in the US, 2017–26
Figure 66: Lidoderm for neuropathic pain – SWOT analysis
Figure 67: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 68: The authors drug assessment summary of Lidoderm for neuropathic pain
Figure 69: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 70: Lyrica for neuropathic pain – SWOT analysis
Figure 71: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 72: The authors drug assessment summary of Lyrica for neuropathic pain
Figure 73: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country, 2017–26
Figure 74: Nucynta ER for neuropathic pain – SWOT analysis
Figure 75: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 76: The authors drug assessment summary of Nucynta ER for neuropathic pain
Figure 77: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country, 2017–26
Figure 78: Cebranopadol for neuropathic pain – SWOT analysis
Figure 79: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 80: The authors drug assessment summary of cebranopadol for neuropathic pain
Figure 81: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
Figure 82: Donaperminogene seltoplasmid for neuropathic pain – SWOT analysis
Figure 83: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 84: The authors drug assessment summary of donaperminogene seltoplasmid for neuropathic pain
Figure 85: Donaperminogene seltoplasmid sales for neuropathic pain in the US, 2017–26
Figure 86: Mirogabalin for neuropathic pain – SWOT analysis
Figure 87: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 88: The authors drug assessment summary of mirogabalin for neuropathic pain
Figure 89: Mirogabalin sales for neuropathic pain in Japan, 2017–26
Figure 90: Raxatrigine for neuropathic pain – SWOT analysis
Figure 91: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 92: The authors drug assessment summary of raxatrigine for neuropathic pain
Figure 93: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
LIST OF TABLES
Table 1: Neuropathic pain drug sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Drug sales across the US, Japan, and five major EU markets, by drug class ($m), 2017–26
Table 3: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype ($m), 2017–26
Table 4: Exchange rates used for calculating prices
Table 5: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 6: Therapies included within neuropathic pain key opinion leader discussions
Table 7: Cymbalta drug profile
Table 8: Cymbalta Phase III data in neuropathic pain syndromes
Table 9: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Gralise drug profile
Table 11: Gralise Phase III data in post-herpetic neuralgia
Table 12: Gralise sales for neuropathic pain in the US ($m), 2017–26
Table 13: Lidoderm drug profile
Table 14: Lidoderm Phase III data in neuropathic pain syndromes
Table 15: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 16: Lyrica drug profile
Table 17: Lyrica Phase III data in diabetic neuropathy
Table 18: Lyrica Phase III data in post-herpetic neuralgia
Table 19: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 20: Nucynta ER drug profile
Table 21: Nucynta ER Phase III data in diabetic neuropathy
Table 22: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 23: Cebranopadol drug profile
Table 24: Cebranopadol Phase II data in neuropathic pain
Table 25: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
Table 26: Donaperminogene seltoplasmid drug profile
Table 27: Donaperminogene seltoplasmid Phase II data in neuropathic pain
Table 28: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
Table 29: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
Table 30: Mirogabalin drug profile
Table 31: Mirogabalin Phase III data in neuropathic pain
Table 32: Mirogabalin Phase II data in neuropathic pain
Table 33: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
Table 34: Raxatrigine drug profile
Table 35: Raxatrigine Phase II data in neuropathic pain
Table 36: Raxatrigine Phase III trials in neuropathic pain
Table 37: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 38: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 39: Therapies discussed in the neuropathic pain key opinion leader primary research study, December 2017
Table 40: Common neuropathic pain conditions and their etiology
Table 41: Treatments available for neuropathic pain across the US, Japan, and five major EU markets
Table 42: International Association for the Study of Pain recommendations
Table 43: Treatment strategies for painful diabetic peripheral neuropathy patients, by country (%)
Table 44: Treatment strategies for post-herpetic neuralgia patients, by country (%)
Table 45: Treatment strategies for chemotherapy-induced peripheral neuropathy, by country (%)
Table 46: Treatment strategies for other chronic neuropathic pain patients, by country (%)
Table 47: Compliance rates of neuropathic pain patients across the US, Japan, and five major EU markets, by therapy type and country
Table 48: Relative importance of unmet needs in neuropathic pain treatment in the US, Japan, and five major EU markets, by country
Table 49: Sources used for painful peripheral diabetic neuropathy analysis in the US, Japan, and five major EU markets
Table 50: Segmentation of total neuropathic pain patients by pain type, by country
Table 51: Total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017–37
Table 52: Profiled key marketed drugs for neuropathic pain
Table 53: Cymbalta drug profile
Table 54: Cymbalta Phase III data in neuropathic pain syndromes
Table 55: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 56: Gralise drug profile
Table 57: Gralise Phase III data in post-herpetic neuralgia
Table 58: Gralise sales for neuropathic pain in the US ($m), 2017–26
Table 59: Lidoderm drug profile
Table 60: Lidoderm Phase III data in neuropathic pain syndromes
Table 61: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 62: Lyrica drug profile
Table 63: Lyrica Phase III data in diabetic neuropathy
Table 64: Lyrica Phase III data in post-herpetic neuralgia
Table 65: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 66: Nucynta ER drug profile
Table 67: Nucynta ER Phase III data in diabetic neuropathy
Table 68: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 69: Profiled pipeline products in development for neuropathic pain
Table 70: Cebranopadol drug profile
Table 71: Cebranopadol Phase II data in neuropathic pain
Table 72: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
Table 73: Donaperminogene seltoplasmid drug profile
Table 74: Donaperminogene seltoplasmid Phase II data in neuropathic pain
Table 75: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
Table 76: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
Table 77: Mirogabalin drug profile
Table 78: Mirogabalin Phase III data in neuropathic pain
Table 79: Mirogabalin Phase II data in neuropathic pain
Table 80: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
Table 81: Raxatrigine drug profile
Table 82: Raxatrigine Phase II data in neuropathic pain
Table 83: Raxatrigine Phase III trials in neuropathic pain
Table 84: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Drug sales across the US, Japan, and five major EU markets, by drug class ($m), 2017–26
Table 3: Drug sales across the US, Japan, and five major EU markets, by neuropathic pain subtype ($m), 2017–26
Table 4: Exchange rates used for calculating prices
Table 5: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 6: Therapies included within neuropathic pain key opinion leader discussions
Table 7: Cymbalta drug profile
Table 8: Cymbalta Phase III data in neuropathic pain syndromes
Table 9: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Gralise drug profile
Table 11: Gralise Phase III data in post-herpetic neuralgia
Table 12: Gralise sales for neuropathic pain in the US ($m), 2017–26
Table 13: Lidoderm drug profile
Table 14: Lidoderm Phase III data in neuropathic pain syndromes
Table 15: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 16: Lyrica drug profile
Table 17: Lyrica Phase III data in diabetic neuropathy
Table 18: Lyrica Phase III data in post-herpetic neuralgia
Table 19: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 20: Nucynta ER drug profile
Table 21: Nucynta ER Phase III data in diabetic neuropathy
Table 22: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 23: Cebranopadol drug profile
Table 24: Cebranopadol Phase II data in neuropathic pain
Table 25: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
Table 26: Donaperminogene seltoplasmid drug profile
Table 27: Donaperminogene seltoplasmid Phase II data in neuropathic pain
Table 28: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
Table 29: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
Table 30: Mirogabalin drug profile
Table 31: Mirogabalin Phase III data in neuropathic pain
Table 32: Mirogabalin Phase II data in neuropathic pain
Table 33: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
Table 34: Raxatrigine drug profile
Table 35: Raxatrigine Phase II data in neuropathic pain
Table 36: Raxatrigine Phase III trials in neuropathic pain
Table 37: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 38: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 39: Therapies discussed in the neuropathic pain key opinion leader primary research study, December 2017
Table 40: Common neuropathic pain conditions and their etiology
Table 41: Treatments available for neuropathic pain across the US, Japan, and five major EU markets
Table 42: International Association for the Study of Pain recommendations
Table 43: Treatment strategies for painful diabetic peripheral neuropathy patients, by country (%)
Table 44: Treatment strategies for post-herpetic neuralgia patients, by country (%)
Table 45: Treatment strategies for chemotherapy-induced peripheral neuropathy, by country (%)
Table 46: Treatment strategies for other chronic neuropathic pain patients, by country (%)
Table 47: Compliance rates of neuropathic pain patients across the US, Japan, and five major EU markets, by therapy type and country
Table 48: Relative importance of unmet needs in neuropathic pain treatment in the US, Japan, and five major EU markets, by country
Table 49: Sources used for painful peripheral diabetic neuropathy analysis in the US, Japan, and five major EU markets
Table 50: Segmentation of total neuropathic pain patients by pain type, by country
Table 51: Total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017–37
Table 52: Profiled key marketed drugs for neuropathic pain
Table 53: Cymbalta drug profile
Table 54: Cymbalta Phase III data in neuropathic pain syndromes
Table 55: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 56: Gralise drug profile
Table 57: Gralise Phase III data in post-herpetic neuralgia
Table 58: Gralise sales for neuropathic pain in the US ($m), 2017–26
Table 59: Lidoderm drug profile
Table 60: Lidoderm Phase III data in neuropathic pain syndromes
Table 61: Lidoderm sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 62: Lyrica drug profile
Table 63: Lyrica Phase III data in diabetic neuropathy
Table 64: Lyrica Phase III data in post-herpetic neuralgia
Table 65: Lyrica sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 66: Nucynta ER drug profile
Table 67: Nucynta ER Phase III data in diabetic neuropathy
Table 68: Nucynta ER sales for neuropathic pain across the US, Japan, and major EU markets, by country ($m), 2017–26
Table 69: Profiled pipeline products in development for neuropathic pain
Table 70: Cebranopadol drug profile
Table 71: Cebranopadol Phase II data in neuropathic pain
Table 72: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
Table 73: Donaperminogene seltoplasmid drug profile
Table 74: Donaperminogene seltoplasmid Phase II data in neuropathic pain
Table 75: Donaperminogene seltoplasmid Phase III trials in neuropathic pain
Table 76: Donaperminogene seltoplasmid sales for neuropathic pain in the US ($m), 2017–26
Table 77: Mirogabalin drug profile
Table 78: Mirogabalin Phase III data in neuropathic pain
Table 79: Mirogabalin Phase II data in neuropathic pain
Table 80: Mirogabalin sales for neuropathic pain in Japan ($m), 2017–26
Table 81: Raxatrigine drug profile
Table 82: Raxatrigine Phase II data in neuropathic pain
Table 83: Raxatrigine Phase III trials in neuropathic pain
Table 84: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
